Drug interactions in palliative care

Citation
Sa. Bernard et E. Bruera, Drug interactions in palliative care, J CL ONCOL, 18(8), 2000, pp. 1780-1799
Citations number
148
Categorie Soggetti
Oncology,"Onconogenesis & Cancer Research
Journal title
JOURNAL OF CLINICAL ONCOLOGY
ISSN journal
0732183X → ACNP
Volume
18
Issue
8
Year of publication
2000
Pages
1780 - 1799
Database
ISI
SICI code
0732-183X(200004)18:8<1780:DIIPC>2.0.ZU;2-4
Abstract
Purpose: This review of drug interactions in palliative care examines the r elevant literature in this area and summarizes the information on interacti ons of drugs, nutrients, and natural products that are used in the palliati ve care setting. particular emphasis is placed on describing the newer info rmation on the cytochrome P450 (CYP) system and the interactions of opioids , anti-depressants, and the antitussive, dextromethorphan. Methods: We performed a search of the MEDLINE database of the rime period f rom 1966 until April 1998, using medical subject headings such as the names of selective serotonin reuptake inhibitors and other relevant medications in palliative care. Literature reviewed included both human and animal arti cles as well as non-English literature,Bibliographies of these articles and the personal libraries of several palliative care specialists were reviewe d. Software developed by The Medical Letter-The Drug Interaction program wa s also used. Results: Drug interactions can be categorized in several ways. Drug-drug in teractions are the most well known and can be kinetic, dynamic, or pharmace utical. Pharmacokinetic interactions can involve CYP 2D6, which acts on dru gs such as codeine and is responsible far its conversion to morphine. Poor metabolizers, either genotypic or due to phenocopying, are at risk for unde rtreatment if not recognized. Pharmacodynamic interactions with dextrometho rphan may produce serotonin syndrome. Conclusion: Drug interactions are important in palliative care as in other aspects of medicine. these interactions are similar to those seen in other areas of medical care but have significant consequences in pain management. Failure to recognize these interactions can lead to either overdosing or u ndertreatment. J Clin Oncol 18:1786-1799. (C) 2000 by American Society of Clinical Oncolog y.